|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1323453976 |
| 003 |
OCoLC |
| 005 |
20231120010648.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220605t20222022maua ob 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|c YDX
|d OPELS
|d OCLCF
|d UKAHL
|d OCLCQ
|d VRC
|d OCLCO
|
| 020 |
|
|
|a 9780323908245
|q (electronic bk.)
|
| 020 |
|
|
|a 0323908241
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323906043
|
| 020 |
|
|
|z 0323906044
|
| 035 |
|
|
|a (OCoLC)1323453976
|
| 050 |
|
4 |
|a R857.M3
|b I56 2022eb
|
| 082 |
0 |
4 |
|a 610.28
|2 23
|
| 245 |
0 |
0 |
|a Immunomodulatory effects of nanomaterials :
|b assessment and analysis /
|c edited by Mahmoud Elsabahy.
|
| 264 |
|
1 |
|a Cambridge, MA ;
|a Kidlington, OX, United Kingdom :
|b Woodhead Publishing,
|c [2022]
|
| 264 |
|
4 |
|c �2022.
|
| 300 |
|
|
|a 1 online resource (xviii, 176 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Woodhead Publishing series in biomaterials
|
| 505 |
0 |
|
|a Front Cover -- Immunomodulatory Effects of Nanomaterials -- Copyright Page -- Contents -- List of contributors -- About the editor -- Preface -- Acknowledgments -- Introduction -- 1 Nanomaterials: classification, composition, and recent advances in synthesis -- 1.1 Introduction to nanotechnology -- 1.2 Terminology of nanotechnology -- 1.3 Unique properties of nanomaterials -- 1.4 Classification of nanomaterials -- 1.4.1 Polymeric nanoparticles -- 1.4.2 Nanoemulsions -- 1.4.3 Inorganic nanoparticles -- 1.4.4 Carbonaceous nanomaterials -- 1.5 Nanomaterial synthesis -- 1.6 Characterization of nanomaterials -- 1.6.1 Stability and surface chemistry -- 1.6.2 Particle size measurement and polydispersity -- 1.6.3 Electron microscopy and imaging -- 1.6.4 Ultraviolet-visible spectroscopy -- 1.7 Concluding remarks and future avenue -- References -- 2 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19* -- 2.1 Coronavirus disease-2019 -- 2.2 Morphological structure and genome -- 2.3 Clinical presentation, radiological features, and laboratory investigations -- 2.4 Therapeutic attempts -- 2.5 Antiviral therapy -- 2.6 Lopinavir/ritonavir and Arbidol -- 2.7 Immune therapy -- 2.7.1 Convalescent plasma therapy -- 2.8 Tocilizumab -- 2.9 Bamlanivimab (LY3819253 or LY-CoV555) and Etesevimab (LY3832479 or LY-CoV016) -- 2.10 Casirivimab (previously REGN10933) and imdevimab (previously REGN10987) -- 2.11 JAK inhibitors -- 2.12 Baricitinib -- 2.13 Ruxolitinib -- 2.14 Jakotinib -- 2.15 Vaccines -- 2.16 Nanoengineered therapeutics and vaccines in development for management of COVID-19 -- 2.16.1 Nanoengineered therapeutics -- 2.16.2 Nanoengineered vaccines -- 2.17 Current status and perspectives -- Acknowledgment -- References -- 3 Nanomaterials and immune system* -- 3.1 Introduction -- 3.2 The immune system.
|
| 505 |
8 |
|
|a 3.2.1 Structure of the immune system -- 3.2.2 Proinflammatory cytokines -- 3.3 Nanomaterials -- 3.4 Cytokines as biomarkers of immunomodulatory properties of nanomaterials -- 3.4.1 Proinflammatory cytokines as biomarkers of nanoparticle immunotoxicity -- 3.4.2 Route of administration -- 3.4.2.1 Intravenous route -- 3.4.2.2 Subcutaneous and dermal routes -- 3.4.2.3 Nasal and oral routes -- 3.4.2.4 Intraperitoneal -- 3.4.3 Endocytic pathways -- 3.4.4 The role of the nanocarriers: physicochemical characteristics -- 3.4.4.1 Size -- 3.4.4.2 Shape and hydrophobicity -- 3.4.4.3 Composition and surface modifications -- 3.4.5 The contribution of the payloads -- 3.5 Mechanisms of nanoparticle immunotoxicity -- 3.6 Relationship between cytokines and adverse reactions -- 3.7 Evaluation of nanoparticle immunotoxicity -- 3.7.1 Multiplexing principles and complications -- 3.7.1.1 Principles -- 3.7.1.2 Complications -- 3.8 Controlling the immunotoxicity of nanomaterials -- 3.8.1 Nanoparticle-related factors -- 3.8.2 Drug-related factors -- 3.9 Conclusions -- References -- 4 Methods for evaluation of the immunomodulatory effects of nanoparticles* -- 4.1 Introduction -- 4.2 Multiplexing technique for evaluation of particulate materials -- 4.3 Preassessment step: optional -- 4.4 Data mining and analysis -- References -- 5 Recommendations and use of multiplex biomarker assays -- 5.1 Introduction -- 5.1.1 Evaluation of multiplex assays -- 5.1.1.1 Selecting the right size of multiplex assay -- 5.1.1.2 Effects of sample matrix -- 5.1.1.3 Reproducibility -- 5.1.1.4 Lot-to-lot variability -- 5.1.2 Unique challenges with multiplexed assays -- 5.1.2.1 Finding the best sample dilution scheme -- 5.1.2.2 Cross-reactivity in multiplexed assays -- 5.1.2.3 Challenges of crosstalk -- 5.1.2.4 Fit for purpose validation of multiplex assays -- 5.1.2.5 Assay sensitivity.
|
| 505 |
8 |
|
|a 5.2 Conclusions -- References -- 6 Precautions during evaluation of immunotoxicity of particulate materials* -- References -- 7 Data analysis and interpretation* -- 7.1 Discussion -- 7.2 Method -- References -- Index -- Back Cover.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Biomedical materials.
|
| 650 |
|
0 |
|a Nanostructured materials
|x Toxicology.
|
| 650 |
|
0 |
|a Nanostructured materials
|x Physiological effect.
|
| 650 |
|
6 |
|a Biomat�eriaux.
|0 (CaQQLa)201-0025723
|
| 650 |
|
6 |
|a Nanomat�eriaux
|0 (CaQQLa)201-0258061
|x Toxicologie.
|0 (CaQQLa)201-0379898
|
| 650 |
|
6 |
|a Nanomat�eriaux
|0 (CaQQLa)201-0258061
|x Effets physiologiques.
|0 (CaQQLa)201-0374337
|
| 650 |
|
7 |
|a Biomedical materials
|2 fast
|0 (OCoLC)fst00832586
|
| 700 |
1 |
|
|a Elsabahy, Mahmoud,
|e editor.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780323908245
|
| 776 |
0 |
8 |
|c Original
|z 0323906044
|z 9780323906043
|w (OCoLC)1284982219
|
| 830 |
|
0 |
|a Woodhead Publishing series in biomaterials.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323906043
|z Texto completo
|
